The latest price target for Spruce Biosciences (NASDAQ:SPRB) was reported by RBC Capital on November 12, 2024. The analyst firm set a price target for $2.00 expecting SPRB to rise to within 12 months (a possible 307.58% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for Spruce Biosciences (NASDAQ:SPRB) was provided by RBC Capital, and Spruce Biosciences reiterated their sector perform rating.

The last upgrade for Spruce Biosciences Inc happened on September 8, 2023 when SVB Leerink raised their price target to $9. SVB Leerink previously had a market perform for Spruce Biosciences Inc.

The last downgrade for Spruce Biosciences Inc happened on March 14, 2024 when RBC Capital changed their price target from $9 to $2 for Spruce Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Spruce Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Spruce Biosciences was filed on November 12, 2024 so you should expect the next rating to be made available sometime around November 12, 2025.

While ratings are subjective and will change, the latest Spruce Biosciences (SPRB) rating was a reiterated with a price target of $2.00 to $2.00. The current price Spruce Biosciences (SPRB) is trading at is $0.49, which is out of the analyst’s predicted range.